Cholinergic deficits in Alzheimer disease (AD) have been well documented. Choline
acetyltransferase (ChAt), the synthetic enzyme for acetylcholine (ACh), is consistently …

In Alzheimer's disease (AD), there is a loss of presynaptic cholinergic markers in the
cerebral cortex, but the nature of cholinergic receptor changes is unclear. In this study,[3 …

The cholinergic receptors are classically divided into two kinds, namely the nicotinic
acetylcholine receptor and the muscarinic acetyl-choline receptor. The existence of these …

Molecular genetic and pharmacological studies have suggested that several subtypes of
nicotinic acetylcholine receptors exist in the mammalian and avian brain. Combining 3H‐(−) …

Ligand binding studies show marked reductions of nicotinic, but not of muscarinic binding
sites in Alzheimer's disease. Using monoclonal antibodies we studied …

Neurochemical and neuropathological changes in the cholinergic system in Alzheimer's and
Parkinson's diseases suggest an important role for this system in cognitive function (Perry …

The cholinergic system, particularly the cortically projecting neurons situated in the basal
forebrain, is clearly involved in a variety of human disorders associated with dementia …

Cholinergic receptors (muscarinic subtypes M1 and M2, and putative nicotinic binding) have
been examined in the hippocampus obtained at autopsy from a variety of patients with …

Nicotinic cholinergic receptors were measured in human frontal cortex using (/sup 3/H)
nicotine and (/sup 3/H) acetylcholine (in the presence of atropine) as receptor ligands. A …